WO2001076574A3 - Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists - Google Patents
Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists Download PDFInfo
- Publication number
- WO2001076574A3 WO2001076574A3 PCT/EP2001/004116 EP0104116W WO0176574A3 WO 2001076574 A3 WO2001076574 A3 WO 2001076574A3 EP 0104116 W EP0104116 W EP 0104116W WO 0176574 A3 WO0176574 A3 WO 0176574A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- combination
- aldosterone synthase
- receptor antagonists
- medical use
- synthase inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002405895A CA2405895A1 (en) | 2000-04-12 | 2001-04-10 | Combination of organic compounds |
NZ521855A NZ521855A (en) | 2000-04-12 | 2001-04-10 | Use of an aldosterone synthase inhibitor in combination with an angiotensin I receptor antagonist or an angiotensin I receptor antagonist plus a dirruretic to treat various conditions |
BR0110079-3A BR0110079A (en) | 2000-04-12 | 2001-04-10 | Combination of organic compounds |
AU2001273938A AU2001273938B2 (en) | 2000-04-12 | 2001-04-10 | Novel medical use of aldosterone synthase inhibitors alone or in combination with ati-receptor antagonists |
EP01940317A EP1282410A2 (en) | 2000-04-12 | 2001-04-10 | Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
AU7393801A AU7393801A (en) | 2000-04-12 | 2001-04-10 | Combination of organic compounds |
PL01358459A PL358459A1 (en) | 2000-04-12 | 2001-04-10 | Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
MXPA02010091A MXPA02010091A (en) | 2000-04-12 | 2001-04-10 | Combination of organic compounds. |
KR1020027013486A KR20020089437A (en) | 2000-04-12 | 2001-04-10 | Combination of organic compounds |
IL15208101A IL152081A0 (en) | 2000-04-12 | 2001-04-10 | Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
KR1020027013874A KR100755768B1 (en) | 2000-04-19 | 2001-04-10 | Methylation of indole compounds using dimethyl carbonate |
JP2001574092A JP2003530343A (en) | 2000-04-12 | 2001-04-10 | Novel pharmaceutical use of aldosterone synthase inhibitor alone or in combination with AT1-receptor antagonist |
HU0301335A HUP0301335A3 (en) | 2000-04-12 | 2001-04-10 | Combination of organic compounds |
SK1461-2002A SK14612002A3 (en) | 2000-04-12 | 2001-04-10 | Novel medical use of aldosterone synthase inhibitors alone or in combination with AT1-receptor antagonists |
NO20024920A NO20024920L (en) | 2000-04-12 | 2002-10-11 | Combination of organic compounds |
US11/291,008 US20060122217A1 (en) | 2000-04-12 | 2005-11-30 | Combination of organic compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19674200P | 2000-04-12 | 2000-04-12 | |
US60/196,742 | 2000-04-12 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/149,107 A-371-Of-International US20030083342A1 (en) | 2000-04-12 | 2001-04-10 | Combination of organic compounds |
US10/826,106 Division US20040204444A1 (en) | 2000-04-12 | 2004-04-15 | Combination of organic compounds |
US10/940,544 Continuation US20050059697A1 (en) | 2000-04-12 | 2004-09-14 | Combination of organic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001076574A2 WO2001076574A2 (en) | 2001-10-18 |
WO2001076574A3 true WO2001076574A3 (en) | 2002-04-25 |
Family
ID=22726655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/004116 WO2001076574A2 (en) | 2000-04-12 | 2001-04-10 | Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1282410A2 (en) |
JP (1) | JP2003530343A (en) |
KR (1) | KR20020089437A (en) |
CN (1) | CN1422152A (en) |
AR (1) | AR032316A1 (en) |
AU (2) | AU2001273938B2 (en) |
BR (1) | BR0110079A (en) |
CA (1) | CA2405895A1 (en) |
HU (1) | HUP0301335A3 (en) |
IL (1) | IL152081A0 (en) |
MX (1) | MXPA02010091A (en) |
NO (1) | NO20024920L (en) |
NZ (1) | NZ521855A (en) |
PE (1) | PE20020082A1 (en) |
PL (1) | PL358459A1 (en) |
RU (1) | RU2002129569A (en) |
SK (1) | SK14612002A3 (en) |
WO (1) | WO2001076574A2 (en) |
ZA (1) | ZA200208204B (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2416152A1 (en) * | 2000-07-27 | 2002-02-07 | Pharmacia Corporation | Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
US6777443B2 (en) | 2001-05-15 | 2004-08-17 | Novartis Ag | Dipeptide derivatives |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
CA2511737A1 (en) * | 2002-12-27 | 2004-07-22 | Takeda Pharmaceutical Company Limited | Body weight gain inhibitor |
SE0300988D0 (en) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
WO2005099695A1 (en) * | 2004-04-19 | 2005-10-27 | Novartis Ag | Drug delivery systems for the prevention and treatment of vascular diseases |
ITTO20040760A1 (en) * | 2004-11-03 | 2005-02-03 | Uni Degli Studi Del Piemonte | USE OF A CORTICOSTEROID IN ASSOCIATION WITH OTHER ACTIVE PRINCIPLES FOR THE TREATMENT OF VASCULAR STENOSIS AND THE PREVENTION OF VASCULAR RESTENOSIS |
EP1674080A1 (en) * | 2004-12-24 | 2006-06-28 | KRKA, D.D., Novo Mesto | Solid pharmaceutical composition comprising valsartan |
EA015108B1 (en) * | 2004-12-24 | 2011-06-30 | КРКА, д.д., НОВО МЕСТО | Process for preparing solid pharmaceutical composition comprising valsartan |
WO2006092430A1 (en) | 2005-03-03 | 2006-09-08 | Universität des Saarlandes | Selective inhibitors of human corticosteroid synthases |
TW200716636A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
GT200600381A (en) | 2005-08-25 | 2007-03-28 | ORGANIC COMPOUNDS | |
EP1842543A1 (en) | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
EP2095819A1 (en) | 2008-02-28 | 2009-09-02 | Maastricht University | N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors |
MX2011012627A (en) | 2009-05-28 | 2011-12-14 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors. |
EP2594557B1 (en) | 2009-05-28 | 2016-08-10 | Novartis AG | Substituted aminopropionic derivatives as neprilysin inhibitors |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
TWI627167B (en) | 2011-07-08 | 2018-06-21 | 諾華公司 | Method of treating atherosclerosis in high triglyceride subjects |
UY35144A (en) | 2012-11-20 | 2014-06-30 | Novartis Ag | APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT |
CN105073762B (en) | 2013-02-14 | 2017-03-08 | 诺华股份有限公司 | Substituted biphenyl butyryl phosphonate derivative as NEP (neutral endopeptidase) inhibitor |
UY35671A (en) | 2013-07-25 | 2015-02-27 | Novartis Ag | SYNTHETIC APELINE POLYPEPTIDE BIOCONJUGATES |
EP3024845A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic polypeptides for the treatment of heart failure |
SG11201704758XA (en) | 2015-01-23 | 2017-08-30 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
JOP20190086A1 (en) | 2016-10-21 | 2019-04-18 | Novartis Ag | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
EP3532056A1 (en) * | 2016-10-27 | 2019-09-04 | Damian Pharma AG | Aldosterone synthase inhibitor |
UY38072A (en) | 2018-02-07 | 2019-10-01 | Novartis Ag | COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME |
BR112020022173A2 (en) * | 2018-05-03 | 2021-02-02 | Damian Pharma Ag | r-fadrozole for use in the treatment of aldostonerism |
UY38485A (en) | 2018-11-27 | 2020-06-30 | Novartis Ag | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) INHIBITORS, METHOD OF TREATMENT, USE AND PREPARATION |
EP3887363A1 (en) | 2018-11-27 | 2021-10-06 | Novartis AG | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
CN113166204A (en) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders |
TW202333563A (en) | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
AR127698A1 (en) | 2021-11-23 | 2024-02-21 | Novartis Ag | NAFTYRIDINOONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252565A (en) * | 1990-04-02 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Haloethyl-substituted steroid enzyme inhibitors |
JPH0971586A (en) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | New bicyclic condensed imidazole derivative |
WO1998003180A2 (en) * | 1996-07-22 | 1998-01-29 | The Victoria University Of Manchester | Use of sex steroids function modulators to treat wounds and fibrotic disorders |
FR2766821A1 (en) * | 1997-07-29 | 1999-02-05 | Sanofi Sa | 1,3-OXAZOLINYL-BIPHENYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNTHESIS INTERMEDIATES |
US5906987A (en) * | 1997-03-10 | 1999-05-25 | Schering Aktiengesellschaft And Board Of Regents | Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors |
WO1999045779A1 (en) * | 1998-03-11 | 1999-09-16 | Smithkline Beecham Corporation | Novel compositions of eprosartan |
US5972921A (en) * | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
WO2000002543A2 (en) * | 1998-07-10 | 2000-01-20 | Novartis Ag | Antihypersensitive combination of valsartan and calcium channel blocker |
-
2001
- 2001-04-10 BR BR0110079-3A patent/BR0110079A/en not_active IP Right Cessation
- 2001-04-10 KR KR1020027013486A patent/KR20020089437A/en not_active Application Discontinuation
- 2001-04-10 CA CA002405895A patent/CA2405895A1/en not_active Abandoned
- 2001-04-10 PL PL01358459A patent/PL358459A1/en not_active Application Discontinuation
- 2001-04-10 HU HU0301335A patent/HUP0301335A3/en unknown
- 2001-04-10 WO PCT/EP2001/004116 patent/WO2001076574A2/en not_active Application Discontinuation
- 2001-04-10 SK SK1461-2002A patent/SK14612002A3/en unknown
- 2001-04-10 NZ NZ521855A patent/NZ521855A/en unknown
- 2001-04-10 JP JP2001574092A patent/JP2003530343A/en active Pending
- 2001-04-10 RU RU2002129569/15A patent/RU2002129569A/en not_active Application Discontinuation
- 2001-04-10 AR ARP010101698A patent/AR032316A1/en not_active Application Discontinuation
- 2001-04-10 AU AU2001273938A patent/AU2001273938B2/en not_active Ceased
- 2001-04-10 EP EP01940317A patent/EP1282410A2/en not_active Withdrawn
- 2001-04-10 PE PE2001000328A patent/PE20020082A1/en not_active Application Discontinuation
- 2001-04-10 CN CN01807917A patent/CN1422152A/en active Pending
- 2001-04-10 IL IL15208101A patent/IL152081A0/en unknown
- 2001-04-10 MX MXPA02010091A patent/MXPA02010091A/en not_active Application Discontinuation
- 2001-04-10 AU AU7393801A patent/AU7393801A/en active Pending
-
2002
- 2002-10-11 NO NO20024920A patent/NO20024920L/en not_active Application Discontinuation
- 2002-10-11 ZA ZA200208204A patent/ZA200208204B/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252565A (en) * | 1990-04-02 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Haloethyl-substituted steroid enzyme inhibitors |
JPH0971586A (en) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | New bicyclic condensed imidazole derivative |
WO1998003180A2 (en) * | 1996-07-22 | 1998-01-29 | The Victoria University Of Manchester | Use of sex steroids function modulators to treat wounds and fibrotic disorders |
US5906987A (en) * | 1997-03-10 | 1999-05-25 | Schering Aktiengesellschaft And Board Of Regents | Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors |
FR2766821A1 (en) * | 1997-07-29 | 1999-02-05 | Sanofi Sa | 1,3-OXAZOLINYL-BIPHENYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNTHESIS INTERMEDIATES |
US5972921A (en) * | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
WO1999045779A1 (en) * | 1998-03-11 | 1999-09-16 | Smithkline Beecham Corporation | Novel compositions of eprosartan |
WO2000002543A2 (en) * | 1998-07-10 | 2000-01-20 | Novartis Ag | Antihypersensitive combination of valsartan and calcium channel blocker |
Non-Patent Citations (7)
Title |
---|
HAGMANN M ET AL: "SC-52458, an orally active angiotensin II-receptor antagonist: Inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers.", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 29, no. 4, 1997, pages 444 - 450, XP001053467, ISSN: 0160-2446 * |
MAKINO N ET AL: "Regression of Hypertrophy After Myocardial Infarction is Produced by the Chronic Blockade of Angiotensin Type 1 Receptor in Rats", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, XX, XX, vol. 28, no. 3, 1996, pages 507 - 517, XP002106098, ISSN: 0022-2828 * |
MASATO H ET AL: "ALGAAS/GAAS/INGAAS DOUBLE-DOPED QUANTUM-WELL HEMTS FOR LOW DISTORTION AMPLIFIER", EXTENDED ABSTRACTS OF THE INTERNATIONAL CONFERENCE ON SOLID STATE DEVICES AND MATERIALS, JAPAN SOCIETY OF APPLIED PHYSICS. TOKYO, JA, 29 August 1993 (1993-08-29), pages 715 - 717, XP000409466 * |
MAXFIELD E K ET AL: "Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats.", DIABETOLOGIA, vol. 36, no. 12, 1993, pages 1230 - 1237, XP001053448, ISSN: 0012-186X * |
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 07 31 July 1997 (1997-07-31) * |
S.BUDAVARI EDITOR: "The Merck Index, 12th Edition", MERCK & CO., INC., WHITEHOUSE STATION, N.J., U.S.A., XP002178362 * |
VIIGIMAA M ET AL: "Tasosartan and hydroclorothiazide as combination therapy in the treatment of severe essential hypertension: Comparison with enalapril.", CARDIOVASCULAR DRUGS AND THERAPY, vol. 14, no. 4, August 2000 (2000-08-01), pages 447 - 449, XP001053452, ISSN: 0920-3206 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001076574A2 (en) | 2001-10-18 |
NZ521855A (en) | 2004-10-29 |
MXPA02010091A (en) | 2003-02-12 |
PE20020082A1 (en) | 2002-02-21 |
BR0110079A (en) | 2002-12-31 |
NO20024920L (en) | 2002-11-27 |
KR20020089437A (en) | 2002-11-29 |
EP1282410A2 (en) | 2003-02-12 |
AU7393801A (en) | 2001-10-23 |
AU2001273938B2 (en) | 2005-03-03 |
NO20024920D0 (en) | 2002-10-11 |
CA2405895A1 (en) | 2001-10-18 |
SK14612002A3 (en) | 2003-05-02 |
RU2002129569A (en) | 2004-03-27 |
JP2003530343A (en) | 2003-10-14 |
ZA200208204B (en) | 2003-10-14 |
PL358459A1 (en) | 2004-08-09 |
CN1422152A (en) | 2003-06-04 |
AR032316A1 (en) | 2003-11-05 |
IL152081A0 (en) | 2003-05-29 |
HUP0301335A2 (en) | 2003-08-28 |
HUP0301335A3 (en) | 2006-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001076574A3 (en) | Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists | |
WO2001076573A3 (en) | Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups | |
AU2003261723A1 (en) | Cxcr4 antagonist and use thereof | |
AU2002323337A1 (en) | Use of dppiv inhibitors as diuretic and anti-hypertensive agents | |
ZA200501677B (en) | Hydantoin derivatives and their use as TACE inhibitors. | |
HUP0300855A3 (en) | Peptidmomimetic protease inhibitors, pharmaceutical compositions and their use | |
MXPA04000586A (en) | Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor. | |
HUP0202682A3 (en) | Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use | |
HUP0600057A2 (en) | Glutaminyl based dpiv inhibitors, pharmaceutical compositions comprising thereof and their use | |
WO2001037785A3 (en) | Novel methods and compositions involving opioids and antagonists thereof | |
HUP0300563A3 (en) | Inhibitors of dipeptidyl peptidase iv, pharmaceutical compositions containing them and their use | |
IL152916A0 (en) | Heteroaryl-phenyl heterobicyclic factor xa inhibitors | |
MXPA03009220A (en) | Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors. | |
WO2002040008A3 (en) | Treatment of sexual dysfunction with non peptide bombesin receptor antagonists | |
WO2002099388A3 (en) | Benzodiazepine bradykinin antagonists | |
HUP0203288A3 (en) | Pyrrole derivatives as phosphodiesterase vii inhibitors, pharmaceutical compositions containing them and their use | |
IL153937A0 (en) | Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors | |
WO2002015933A3 (en) | Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser | |
WO2002015892A3 (en) | Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors | |
AU2003233127A1 (en) | Non-peptide gnrh agents, pharmaceutical compositions and methods for their use | |
AU2003227186A1 (en) | Spiro derivatives and adhesion molecule inhibitors comprising the same as the active ingredient | |
AUPQ570100A0 (en) | Beta-alanine derivatives and their use as receptor antagonists | |
AU2002302735A1 (en) | 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists | |
AU2003220523A1 (en) | Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents | |
PL369736A1 (en) | New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10149107 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001940317 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001273938 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 152081 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 521855 Country of ref document: NZ Ref document number: 1020027013486 Country of ref document: KR Ref document number: IN/PCT/2002/1650/CHE Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2001 574092 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2405895 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14612002 Country of ref document: SK Ref document number: PV2002-3380 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/08204 Country of ref document: ZA Ref document number: PA/a/2002/010091 Country of ref document: MX Ref document number: 018079172 Country of ref document: CN Ref document number: 200208204 Country of ref document: ZA Ref document number: 02091881 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002129569 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200201026 Country of ref document: VN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027013486 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001940317 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-3380 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 521855 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 521855 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001273938 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2002-3380 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001940317 Country of ref document: EP |